Evidence map›Paper›PMID 32572821›Full record

ArticlePathology oncology research : POR2020

Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions.

Stéphane Rossat, Hervé Perrier, Marine Lefevre, Christophe Louvet, Nathalie Le Berre, Jérôme Chamois, Maryline Dorel, Daniel Vacque, Angélique Guillaudeau, Dominique Genet and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Performance of IdyllaInternational journal of clinical oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Stéphane RossatMedipath, Aix-Marseille, Éguilles, France.
Hervé PerrierSaint-Joseph Hospital, Marseille, France.
Marine LefevreInstitute Montsouris, Paris, France.
Christophe LouvetInstitute Montsouris, Paris, France.
Nathalie Le BerreOuest Pathologie, Rennes, France.
Jérôme ChamoisPrivate Hospital St Grégoire, Saint-Grégoire, France.
Maryline DorelAlizés Pathology Center, Baie-Mahault, Guadeloupe, France.
Daniel VacqueLes Eaux Claires Clinic, Baie-Malhault, Guadeloupe, France.
Angélique GuillaudeauLimoges Polyclinic, Limoges, France.
Dominique GenetChénieux Clinic, Limoges, France.
Evelyne MailletPathologie Center MAILLET Evelyne, Ste Clotilde, La Réunion, France.
Simon TribyAMGEN France, Boulogne-Billancourt, France.
Jean-Christophe SabourinRouen University Hospital, Rouen, France. sabourinjc@gmail.com.ORCID http://orcid.org/0000-0001-5490-066X
Institute Mutualiste Montsouris · FRInstitut Pasteur de la Guadeloupe · GPAix-Marseille Université · FRCentre Hospitalier privé Saint Grégoire · FRCentre Hospitalier Universitaire de La Réunion · FRHôpital Charles-Nicolle · FRHôpital Saint Joseph · FRInstitut Agro Rennes-Angers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In some situations, there is a need for rapid mutation tests for guiding clinical decisions and starting targeted therapies with minimal delays. In this study we evaluated the turnaround time before and after the implementation of a fully automated multiplex assay for KRAS and NRAS/BRAF mutation tests (Idylla™ platform, Biocartis) in metastatic colorectal cancer. The objective of this project was to compare the turnaround times in 2017-2018 with the fully automated multiplex assay to the 2016 results with previous methods. Centers with a number of tests for metastatic colorectal cancer > 100 yearly and a usual turnaround time ≥ 3 weeks for mutation detection were selected. Results of 505 KRAS tests and 369 NRAS/BRAF tests were transmitted by 10 centers. The mean turnaround time from test prescription to reception of results was reduced from 25.8 days in 2016 to 4.5 days in 2017-2018. In conclusion, this pilot project shows that the Idylla™ platform for testing KRAS and NRAS/BRAF mutations allows an optimized turnaround time from test prescription to reception of results.

Indexed as

AutomationColorectal NeoplasmsDNA Mutational AnalysisGTP PhosphohydrolasesHumansMembrane ProteinsMutationPathology, MolecularPilot ProjectsProspective StudiesProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Time FactorsBRAF protein, humanGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAF mutationKRAS mutationMetastatic colorectal cancerMutation analysis

Identifiers

PMID32572821
OpenAlexW3036021180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.